- Home
- PRME vs DNA Comparison
PRME vs DNA Comparison
Compare PRME & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- DNA
- Stock Information
- Founded
- PRME 2019
- DNA 2008
- Country
- PRME United States
- DNA United States
- Employees
- PRME N/A
- DNA N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRME Health Care
- DNA Health Care
- Exchange
- PRME Nasdaq
- DNA Nasdaq
- Market Cap
- PRME 693.5M
- DNA 731.1M
- IPO Year
- PRME 2022
- DNA N/A
- Fundamental
- Price
- PRME $4.67
- DNA $10.60
- Analyst Decision
- PRME Buy
- DNA Hold
- Analyst Count
- PRME 6
- DNA 2
- Target Price
- PRME $8.88
- DNA $9.50
- AVG Volume (30 Days)
- PRME 2.9M
- DNA 1.6M
- Earning Date
- PRME 11-11-2025
- DNA 11-11-2025
- Dividend Yield
- PRME N/A
- DNA N/A
- EPS Growth
- PRME N/A
- DNA N/A
- EPS
- PRME N/A
- DNA N/A
- Revenue
- PRME $4,961,000.00
- DNA $230,815,000.00
- Revenue This Year
- PRME $179.58
- DNA N/A
- Revenue Next Year
- PRME N/A
- DNA $13.73
- P/E Ratio
- PRME N/A
- DNA N/A
- Revenue Growth
- PRME 739.42
- DNA 25.21
- 52 Week Low
- PRME $1.11
- DNA $5.00
- 52 Week High
- PRME $5.17
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- PRME 67.60
- DNA 43.56
- Support Level
- PRME $3.09
- DNA $9.95
- Resistance Level
- PRME $4.18
- DNA $11.97
- Average True Range (ATR)
- PRME 0.31
- DNA 0.79
- MACD
- PRME 0.11
- DNA -0.16
- Stochastic Oscillator
- PRME 98.14
- DNA 22.71
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.